Clinical trials have been primarily driven by a site-centric approach i.e., face-to-face interactions at the site. With COVID-19 severely impacting the functioning of traditional clinical trials, it has opened a world of opportunities and possibilities to move to the next generation of clinical trials augmented by digital technologies with patient at its center.
TCS partnered with Merck to realize the latter’s vision on a digitally enabled trials platform (DETP), leveraging the Decentralized Trials solution from TCS ADD offering. The DETP was aimed at resolving challenges around protocol impact, supplier qualification and GxP procedures, managing data privacy and calculating RoI. The partnership facilitated a host of features being actively tested, viz-a-viz, electronic date capture from device and reporting, auto reminders, interim data storage, API, passive data transfer and BYOD.